Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica

PHASE3UnknownINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

September 30, 2010

Study Completion Date

December 31, 2011

Conditions
Polymyalgia Rheumatica
Interventions
DRUG

infliximab

Infliximab 5 mg/kg. i.v. at week 0, 2, 6, 14 y 22.

DRUG

inactive powder

Inactive powder. i.v. at week 0, 2, 6, 14 y 22.

Trial Locations (1)

39008

Reumatology division, Hospital Universitario Marques de Valdecilla, Santander

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Schering-Plough

INDUSTRY

lead

Hospital Universitario Marqués de Valdecilla

OTHER

NCT01423591 - Infliximab Therapy in Patients With Refractory Polymyalgia Rheumatica | Biotech Hunter | Biotech Hunter